# Cathie Wood Sees Value in Ionis Dip | Business and Finance News

Page: https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/cathie-wood-sees-value-in-ionis-dip-business-and-finance-news
Text version: https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/cathie-wood-sees-value-in-ionis-dip-business-and-finance-news.md
Podcast: [Business News Today | 2 Min News | The Daily News Now!](https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192)
Published: 2026-07-18T15:01:18+00:00
Episode link: https://sources.thednn.ai/93a91af4807d9bac
Audio file: https://api.fastcast.ai/audio/4b8addee-8a8b-4e85-8b17-4ead5974263b.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/cathie-wood-sees-value-in-ionis-dip-business-and-finance-news
Duration seconds: 136

## Resource

Cathie Wood’s ARK Genomic Revolution ETF just dumped $15 million into Ionis Pharmaceuticals—right after the stock tanked 37% following a failed late-stage trial for its heart drug eplontersen. But here’s the twist: Ionis isn’t just betting on that one flop. They’ve got Tryngolza, a recently approved drug they’re now commercializing themselves—keeping bigger profits instead of licensing out. The pivot means more risk, but also higher rewards, as they slash prices to boost access and aim for cash flow break-even by 2028. With a solid pipeline including an FDA-reviewed drug for Alexander disease and pelacarsen in late-stage trials for stroke and heart attack prevention, Ionis’ RNA-targeted tech gives them a proven edge. Wood’s move? A bold, value-driven bet on Ionis’ long-term potential—despite the bumps ahead. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/93a91af4807d9bac

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/cathie-wood-sees-value-in-ionis-dip-business-and-finance-news/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/cathie-wood-sees-value-in-ionis-dip-business-and-finance-news.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.